Systematic Review of Genetic-Related Risk Factor and Inhibitor Epidemiology in People with Severe Hemophilia a from Africa: A 2023 Update
Tatiana Baglo *
Hematology Laboratory, National Teaching Hospital Hubert Koutoukou Maga of Cotonou, Benin and Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.
Alban Zohoun
Hematology Laboratory, National Teaching Hospital Hubert Koutoukou Maga of Cotonou, Benin and Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.
Simon Azonbakin
Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin and Laboratory of Histology - Reproductive Biology, Cytogenetics and Medical Genetics, Human Biology Unit, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.
Bienvenu Houssou
Hematology Laboratory, National Teaching Hospital Hubert Koutoukou Maga of Cotonou, Benin.
Romaric Massi
Hematology Laboratory, National Teaching Hospital Hubert Koutoukou Maga of Cotonou, Benin.
Charlotte Orou Guiwa
Hematology Laboratory, National Teaching Hospital Hubert Koutoukou Maga of Cotonou, Benin.
Ludovic Anani
Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.
Dorothée Kindé Gazard
Hematology Laboratory, National Teaching Hospital Hubert Koutoukou Maga of Cotonou, Benin and Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.
Awa Omar Touré Fall
Hematology Laboratory of the Aristide le Dantec Hospital, Dakar, Senegal and Pharmacy and Odontostomatology, Faculty of Medicine, Cheikh Anta Diop University of Dakar, Dakar, Senegal.
*Author to whom correspondence should be addressed.
Abstract
Background and Aims: Prevalence of factor VIII inhibitors in patients with hemophilia A varies from study to study, ranging from 15% to 30%. The important risk of inhibitor development is factor VIII mutation responsible for hemophilia A. Few studies have reported factor VIII mutations in Africa. The aim of this study was to review on FVIII gène mutations of severe hemophilia A in Africa and those associated with inhibitor development.
Study Design and Methodology: A systematic review was carried out using the electronic databases Pubmed, Science Direct, Index Medicus Global and African Journals online and the key words "hemophilia A", "inhibitor", "genetic" and "Africa". Studies written in French or English on the African continent and published between 2012 and 2023 were included. Publications relating to acquired hemophilia and duplicates were excluded. In the end, 17 articles were selected.
Results: The factor VIII mutations involved in severe hemophilia A in Africa are variable, consisting of intron 22 inversion, large or point deletions, nonsense and missense mutations and splicing abnormalities. Among the latter, numerous previously unrecorded mutations have been identified, and a single case of intron 1 inversion has been found in Algeria. Prevalence of factor VIII inhibitors in severe hemophilia A in Africa varies between 7,8% and 30%. Genetic abnormalities associated with inhibitors include intron 22 inversion, large deletions such as exon 1-13 deletion, nonsense mutations and c.1010-2A>G mutation.
Conclusion: A better knowledge of the factor VIII mutations involved in severe hemophilia A in Africa will help improve patient management.
Keywords: Hemophilia, factor VIII, inhibitor, genetic mutations, Africa
How to Cite
References
Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, et al. Data and Demographics Committee of the World Federation of Hemophilia. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019 Oct 15;171(8):540-546.
DOI: 10.7326/M19-1208.
Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801-9.
DOI: 10.1016/S0140-6736(03)13405-8
Alcalay M. Muscular complications of hemophilia. Arch Pediatr. 2009;16(2):196-200. French.
DOI: 10.1016/j.arcped.2008.11.007
Cormier M, Batty P, Tarrant J, Lillicrap D. Advances in knowledge of inhibitor formation in severe haemophilia A. Br J Haematol. 2020;189(1):39-53. DOI: 10.1111/bjh.16377
Goudemand J. Les anticorps anti Facteur VIII chez l’hémophile. Hématologie.2001;7: 170–183.
Calvez T, Chambost H, d'Oiron R, Dalibard V, Demiguel V, Doncarli A et al. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia-A. Haematologica. 2018; 103(1):179-189.
DOI: 10.3324/haematol.2017.174706.
Franchini M, Coppola A, Rocino A, Santagostino E, Tagliaferri A, Zanon E et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia-A: A 2013 update. 2013;39(7): 752-66.
DOI: 10.1055/s-0033-1356715. 8
Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Hemophilia 2006;12:15–22.
Seck M, Costa C, Faye BF, Sy Bah D, Touré SA, Dieng N, et al. Molecular diagnosis of hemophilia A in patients from Senegal. Haemophilia. 2017;23(3):e225-e227.
DOI: 10.1111/hae.13207
Touré SA, Seck M, Sy D, Senghor AB, Faye BF, Diop S. Clinical outcome and incidence of inhibitor development in severe hemophilia patients receiving low-dose prophylaxis: A 3-year follow-up study in Senegal, West Africa. Hematol Transfus Cell Ther. 2023;45 Suppl 2: S95-S100.
DOI: 10.1016/j.htct.2022.04.004.
Lochan A, Macaulay S, Chen WC, Mahlangu JN, Krause A. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia. 2014;20(5):687- 92.
DOI: 10.1111/hae.12436.
Bouyadmar M, Khorassani ME, Kababri ME, Kili A, Hessissen L. The prevalence of anti-factor VIII and anti-factor IX antibodies among patients with hemophilia in Rabat, Morocco: A single center experience. Pan Afr Med J. 2022;14(41):126.
DOI: 10.11604/pamj.2022.41.126.29571
Balôgôg PN, Tagny CT, Ndoumba A, Mbanya D. FVIII and FIX inhibitors in people living with hemophilia in Cameroon, Africa: A preliminary study. Int J Lab Hematol. 2014;36(5):566-70.
DOI: 10.1111/ijlh.12190.
Mafisa L, Dlova AN, Moodley V. The profile of patients with hemophiliamanaged at a hemophiliatreatment centre in Pretoria, Gauteng. S Afr Fam Pract. 2022;64(1): e1-e7.
DOI: 10.4102/safp.v64i1.5551
Lambert C, Meité N, Sanogo I, Lobet S, Adjambri E, Eeckhoudt S et al. Hemophilia in Côte d’Ivoire (the Ivory Coast) in 2017: Extensive data collection as part of the World Federation of Hemophilia’s twinning programme. Haemophilia. 2019;25(2):236-243.
DOI: 10.1111/hae.13682.
Ghali O, El Borgi W, El Mahmoudi H, Ben Lakhal F, Fekih Salem S, Achour M et al.. Prévalence des inhibiteurs anti-FVIII chez les enfants hémophiles A: Experience d’un centre d’hemophilie et revue de la litterature. JI M Sfax 2020;35:45–49.
Touré SA, Seck M, Sy D, Bousso ES, Faye BF, Diop S. Life-threatening bleeding in patients with hemophilia (PWH): A 10-year cohort study in Dakar, Senegal.pdf. Hematology. 2022 Dec;27(1):379- 383.
DOI: 10.1080/16078454.2022.2047286.
Lambert C, Lannoy N, Meité N, Sanogo I, Eeckhoudt S, Hermans C. Inhibitor epidemiology and genetic-related risk factors in people with hemophilia from Côte d’Ivoire. Haemophilia. 2020 Jan;26(1):79-85. doi: 10.1111/hae.13902.
Zemani-Fodil F, Abdi M, Fodil M, Samia Aberkane M, Mesli N, Belazaar M et al. Factor 8 Gene Mutations and Risk of Inhibitor Development in Hemophilia-A Algerian Patients. J Pharmacogenomics Pharmacoproteomics 2014;05:1–4.
DOI: 10.4172/2153-0645.1000124
Sherief LM, Gaber OA, Youssef HM, Sherbiny HS, Mokhtar WA, Ali AAA, et al. Factor VIII inhibitor development in Egyptian hemophilia patients: Does intron 22 inversion mutation play a role? Ital J Pediatr. 2020;46(1):129.
DOI: 10.1186/s13052-020-00878-5.
Elmahmoudi H, Khodjet-el-khil H, Wigren E, Jlizi A, Zahra K, Pellechia D, et al. First report of molecular diagnosis of Tunisian PwH A: Identification of 8 novel causative mutations. Diagn Pathol. 2012 Aug 10;7:93.
DOI: 10.1186/1746-1596-7-93.
Abdi M, Zemani-Fodil F, Fodil M, Aberkane MS, Touhami H, Saidi-Mehtar N, et al. First molecular analysis of F8 gene in Algeria: Identification of two novel mutations. Clin Appl Thromb Hemost. 2014;20(7):741-8.
DOI: 10.1177/1076029613513321.
Bardi E, Astermark J. Genetic risk factors for inhibitors in hemophiliaA. Eur J Haematol 2015;94:7–10.
DOI: 10.1111/ejh.12495.
Howard TE, Viel KR, Karl M. Fernstrom B, Deshpande S, Ameri A, et al. Allelically Mismatched Replacement Therapy Due to Common African−Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia−A Patients of African−Descent. Blood 2006;108(11): 765–765.
DOI.org/10.1182/blood.V108.11.765.765
Gunasekera D, Ettinger RA, Nakaya Fletcher S, James EA, Liu M, Barrett JC et al. Factor VIII gene variants and inhibitor risk in African American hemophilia-A patients. Blood 2015; 126(7):895-904.
DOI: 10.1182/blood-2014-09-599365
Elmahmoudi H, Khodjet-el-khil H, Wigren E, Jlizi A, Zahra K, Pellechia D et al. First report of molecular diagnosis of Tunisian PwH A: Identification of 8 novel causative mutations. Diagn Pathol. 2012 Aug 10;7:93.
DOI: 10.1186/1746-1596-7-93.
Diop S, Haffar A, Mahlangu J, Chami I, Kitchen S, Pierce G. Improving access to hemophilia care in sub-Saharan Africa by capacity building. Blood Adv. 2019;3(Suppl 1):1-4.
DOI: 10.1182/bloodadvances.
Mahony BO, Black C. Expanding Hemophilia Care in Developing Countries. Semin Thromb Hemost. 2005 Nov;31(5): 561-8.
DOI: 10.1055/s-2005-922228
Mbanya DN, Diop S, Ndoumba Mintya AN, El Kiaby M. Hemophilia care in Africa: Status and challenges. Transfus Clin Biol. 2021;28(2):158-162.
DOI: 10.1016/j.tracli.2021.01.008
Davies J, Abimiku A, Alobo M, Mullan Z, Nugent R, Schneidman M et al. Sustainable clinical laboratory capacity for health in Africa. Lancet Glob Health. 2017 Mar;5(3):e248-e249.
DOI: 10.1016/S2214-109X(17)30024-4
Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in PwH : A single-centre experience over 34 years. 1964 – 97. 1964-97. Br J Haematol. 1999 Mar;104(4):909-14.
DOI: 10.1046/j.1365-2141.1999.01268.x.
Aronis S, Platokouki H, Kapsimali Z, Adamtziki E, Kolokithas A, Mitsika A. Prevalence of inhibitor formation in a cohort of haemophilic children exposed to several products of various purities. Haemophilia. 1995;1(4):236-42.
DOI: 10.1111/j.1365-2516.1995.tb00082.x.
Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost. 1992;67(6): 600-2
Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C et al. Inhibitors of Factor VIII in Black Patients with Hemophilia. N Engl J Med. 2009 Apr 16;360(16):1618-27.
DOI: 10.1056/NEJMoa075760
Erratum in: N Engl J Med. 2009 Jul 30;361(5):544.
Liu Q, Nozari G, Sommer SS. Single-Tube Polymerase Chain Reaction for Rapid Diagnosis of the Inversion Hotspot of Mutation in Hemophilia A. Blood. 1998 Aug 15;92(4):1458-9.
Erratum in: Blood 1999 Mar 15;93(6):2141.
Mosaad RM, Amr KS, Rabie EA, Mostafa NO, Habib SA, El-Kamah GY.Genomic alterations in the F8 gene correlating with severe hemophilia-A in Egyptian patients. Mol Genet Genomic Med. 2021 Feb;9(2): e1575.
DOI: 10.1002/mgg3.1575.
UKHCDO. Practice Guidelines for the Molecular Diagnosis of HemophiliaA. Clin Mol Genet Soc 2008;1–11.
Kloppers JF, Janse van Rensburg WJ. Rapid identification of the intron 22 inversion in haemophilia A. Haemophilia. 2017;23(1):e55-e57.
DOI: 10.1111/hae.13142.
Kloppers JF, Marx GM, Rensburg WJJ Van. Intron 22 inversion real-time polymerase chain reaction detection in hemophiliaA families from central South Africa. South African Med J 2019;109: 876–879.
Yunis LK, Linares A, Cabrera E, Yunis JJ. Systematic molecular analysis of hemophilia A patients from Colombia. Genet Mol Biol .2018;41(4):750-757.
DOI: 10.1590/1678-4685-GMB-2017-0072.
Mantilla-Capacho JM, Beltrán-Miranda CP, Luna-Záizar H, Aguilar-López L, Esparza-Flores MA, López-Guido B, et al. Frequency of Intron 1 and 22 Inversions of Factor VIII Gene in Mexican Patients With Severe Hemophilia-A. Am J Hematol 2007; 82(4):283–287.
DOI: 10.1002/ajh.20865.
Keeney S, Mitchell M, Goodeve A; UK Haemophilia Center Doctors' Organization Haemophilia Genetics Laboratory Network. The molecular analysis of haemophilia A: A guideline from the UK haemophilia centre doctors' organization haemophilia genetics laboratory network. Haemophilia. 2005;11(4):387-97.
DOI: 10.1111/j.1365-2516.2005.01111.x.
Abdulqader AMR, Mohammed AI, Rachid S, Ghoraishizadeh P, Mahmood SN. Identification of the Intron 22 and Intron 1 Inversions of the Factor VIII Gene in Iraqi Kurdish Patients With Hemophilia A. Clin Appl Thromb Hemost. 2020;26:1-7.
DOI: 10.1177/1076029619888293.
Sattar A, Hussain S, Ullah MI, Mahmood S, Mohsin S. Screening of Intron 1 Inversion of the Factor VIII Gene in 130 Patients with Severe Hemophilia A from a Pakistani Cohort. Turk J Haematol. 2017;34(3):278-279.
DOI: 10.4274/tjh.2017.0031.
Bril WS, MacLean PE, Kaijen PH, van den Brink EN, Lardy NM, Fijnvandraat K et al. HLA class II genotype and factor VIII inhibitors in mild hemophiliaA patients with an Arg593 to Cys mutation. Hemophilia 2004;10 (5): 509–514.
DOI: 10.1111/j.1365-2516.2004.01011.x
McGill JR, Simhadri VL, Sauna ZE. HLA Variants and Inhibitor Development in Hemophilia-A: A Retrospective Case-Controlled Study Using the ATHNdataset. Front Med (Lausanne) 2021;8(663396).
DOI: 10.3389/fmed.2021.663396
Kim HY, Cho JH, Kim HJ, Chung HS, Kim SH, Lee KO et al. Ethnicity-specific impact of HLA I/II genotypes on the risk of inhibitor development: data from Korean patients with severe hemophilia-A. Ann Hematol. 2018;97(9):1695-1700.
DOI: 10.1007/s00277-018-3358-x.
Schwarz J, Astermark J, Menius ED, Carrington M, Donfield SM, Gomperts ED et al. F8 haplotype and inhibitor risk: Results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Hemophilia 2013;19 (1): 113–118. DOI: 10.1111/hae.12004
Elmahmoudi H, Belhedi N, Jlizi A, Zahra K, Meddeb B, Ben Ammar Elgaaied A et al. Factor VIII haplotypes frequencies in Tunisian PwH A. Diagn Pathol. 2011;6(54). DOI: 10.1186/1746-1596-6-54.
Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK; MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia-A. Blood 2006; 107(8):3167-72. DOI: 10.1182/blood-2005-09-3918
Mafisa L, Dlova AN, Moodley V. The profile of patients with haemophilia managed at a haemophilia treatment centre in Pretoria, Gauteng. S Afr Fam Pract 2022;64(1): e1-e7.
DOI: 10.4102/safp.v64i1.5551